神经科指南

订阅

MedSci主页 / 所有栏目 / 神经科指南

阿尔茨海默病与帕金森病步态分析的中国专家共识

2021-11-03 中国老年保健协会阿尔茨海默病分会 中华老年心脑血管病杂志

阿尔茨海默病神经变性疾病

流行病学调查指出我国阿尔茨海默病(Alz-heimer’s disease, AD)患病总人数近1000万,帕金森病(Parkinson disease, PD)患者总人数近300万[1-

中文标题：

阿尔茨海默病与帕金森病步态分析的中国专家共识

发布机构：

中国老年保健协会阿尔茨海默病分会

发布日期：

2021-11-03

简要介绍：

流行病学调查指出我国阿尔茨海默病(Alz-heimer’s disease, AD)患病总人数近1000万,帕金森病(Parkinson disease, PD)患者总人数近300万[1-2]。AD和PD是最常见的神经系统变性疾病,起病隐匿且早期诊断困难,可导致患者运动、认知功能的障碍直至全部能力丧失,我国每年医疗和护理支出达数万亿人民币[3]。

相关资料下载：
[AttachmentFileName(sort=1, fileName=阿尔茨海默病与帕金森病步态分析的中国专家共识.pdf)] GetToolGuiderByIdResponse(projectId=1, id=b9dac1c00225eada, title=阿尔茨海默病与帕金森病步态分析的中国专家共识, enTitle=, guiderFrom=中华老年心脑血管病杂志, authorId=0, author=, summary=流行病学调查指出我国阿尔茨海默病(Alz-heimer’s disease, AD)患病总人数近1000万,帕金森病(Parkinson disease, PD)患者总人数近300万[1-, cover=https://img.medsci.cn/2021117/1636299170781_5579292.jpg, journalId=0, articlesId=null, associationId=2110, associationName=中国老年保健协会阿尔茨海默病分会, associationIntro=中国老年保健协会阿尔茨海默病分会, copyright=0, guiderPublishedTime=Wed Nov 03 00:00:00 CST 2021, originalUrl=, linkOutUrl=, content=<p><span style="color: #333333;">流行病学调查指出我国阿尔茨海默病(Alz-heimer&rsquo;s disease, AD)患病总人数近1000万,帕金森病(Parkinson disease, PD)患者总人数近300万[1-2]。AD和PD是最常见的神经系统变性疾病,起病隐匿且早期诊断困难,可导致患者运动、认知功能的障碍直至全部能力丧失,我国每年医疗和护理支出达数万亿人民币[3]。</span></p>, tagList=[TagDto(tagId=787, tagName=阿尔茨海默病), TagDto(tagId=5308, tagName=神经变性疾病)], categoryList=[CategoryDto(categoryId=17, categoryName=神经科, tenant=100), CategoryDto(categoryId=85, categoryName=指南&解读, tenant=100), CategoryDto(categoryId=21100, categoryName=达仁堂循证e学界, tenant=100)], articleKeywordId=0, articleKeyword=, articleKeywordNum=6, guiderKeywordId=787, guiderKeyword=阿尔茨海默病, guiderKeywordNum=6, haveAttachments=1, attachmentList=null, guiderType=0, guiderArea=共识, guiderLanguage=0, guiderRegion=3, opened=0, paymentType=, paymentAmount=10, recommend=0, recommendEndTime=null, sticky=0, stickyEndTime=null, allHits=45243, appHits=224, showAppHits=0, pcHits=2486, showPcHits=45019, likes=1, shares=30, comments=7, approvalStatus=1, publishedTime=Tue Nov 16 23:57:01 CST 2021, publishedTimeString=2021-11-03, pcVisible=1, appVisible=1, editorId=5579292, editor=FUNNYMAN, waterMark=0, formatted=0, memberCards=[], isPrivilege=0, deleted=0, version=4, createdBy=null, createdName=FUNNYMAN, createdTime=Sun Nov 07 23:37:26 CST 2021, updatedBy=4754896, updatedName=小小医者, updatedTime=Sat Jan 06 11:57:08 CST 2024, courseDetails=[], otherVersionGuiders=[], isGuiderMember=false, ipAttribution=, attachmentFileNameList=[AttachmentFileName(sort=1, fileName=阿尔茨海默病与帕金森病步态分析的中国专家共识.pdf)])
阿尔茨海默病与帕金森病步态分析的中国专家共识.pdf
下载请点击：
评论区 (7)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1071046, encodeId=6aa910e104619, content=非常好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=86, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=44b85482961, createdName=jianglan, createdTime=Wed Nov 17 10:52:09 CST 2021, time=2021-11-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1068115, encodeId=0f0910681157b, content=非常好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=106, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f3dd1885795, createdName=ms1812733236525890, createdTime=Mon Nov 08 13:58:58 CST 2021, time=2021-11-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1068047, encodeId=25a7106804eba, content=谢谢分享，非常好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=103, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c1f21454840, createdName=leer10103, createdTime=Mon Nov 08 09:29:31 CST 2021, time=2021-11-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1068042, encodeId=9b5610680425a, content=谢谢分享, beContent=null, objectType=guider, channel=null, level=null, likeNumber=106, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200804/f084cf5655364e4d991cbdc7e0a728c8/6011c4d8028d4509b1d5c06d7a966256.jpg, createdBy=6c405125125, createdName=凝香儿, createdTime=Mon Nov 08 09:23:20 CST 2021, time=2021-11-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1067999, encodeId=5329106e999e2, content=谢谢分享, beContent=null, objectType=guider, channel=null, level=null, likeNumber=112, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=644b2182796, createdName=1207866fm50(暂无昵称), createdTime=Mon Nov 08 08:34:30 CST 2021, time=2021-11-08, status=1, ipAttribution=)]
    2021-11-17 jianglan

    非常好

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=1071046, encodeId=6aa910e104619, content=非常好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=86, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=44b85482961, createdName=jianglan, createdTime=Wed Nov 17 10:52:09 CST 2021, time=2021-11-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1068115, encodeId=0f0910681157b, content=非常好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=106, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f3dd1885795, createdName=ms1812733236525890, createdTime=Mon Nov 08 13:58:58 CST 2021, time=2021-11-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1068047, encodeId=25a7106804eba, content=谢谢分享，非常好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=103, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c1f21454840, createdName=leer10103, createdTime=Mon Nov 08 09:29:31 CST 2021, time=2021-11-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1068042, encodeId=9b5610680425a, content=谢谢分享, beContent=null, objectType=guider, channel=null, level=null, likeNumber=106, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200804/f084cf5655364e4d991cbdc7e0a728c8/6011c4d8028d4509b1d5c06d7a966256.jpg, createdBy=6c405125125, createdName=凝香儿, createdTime=Mon Nov 08 09:23:20 CST 2021, time=2021-11-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1067999, encodeId=5329106e999e2, content=谢谢分享, beContent=null, objectType=guider, channel=null, level=null, likeNumber=112, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=644b2182796, createdName=1207866fm50(暂无昵称), createdTime=Mon Nov 08 08:34:30 CST 2021, time=2021-11-08, status=1, ipAttribution=)]
    2021-11-08 ms1812733236525890

    非常好

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1071046, encodeId=6aa910e104619, content=非常好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=86, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=44b85482961, createdName=jianglan, createdTime=Wed Nov 17 10:52:09 CST 2021, time=2021-11-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1068115, encodeId=0f0910681157b, content=非常好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=106, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f3dd1885795, createdName=ms1812733236525890, createdTime=Mon Nov 08 13:58:58 CST 2021, time=2021-11-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1068047, encodeId=25a7106804eba, content=谢谢分享，非常好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=103, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c1f21454840, createdName=leer10103, createdTime=Mon Nov 08 09:29:31 CST 2021, time=2021-11-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1068042, encodeId=9b5610680425a, content=谢谢分享, beContent=null, objectType=guider, channel=null, level=null, likeNumber=106, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200804/f084cf5655364e4d991cbdc7e0a728c8/6011c4d8028d4509b1d5c06d7a966256.jpg, createdBy=6c405125125, createdName=凝香儿, createdTime=Mon Nov 08 09:23:20 CST 2021, time=2021-11-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1067999, encodeId=5329106e999e2, content=谢谢分享, beContent=null, objectType=guider, channel=null, level=null, likeNumber=112, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=644b2182796, createdName=1207866fm50(暂无昵称), createdTime=Mon Nov 08 08:34:30 CST 2021, time=2021-11-08, status=1, ipAttribution=)]
    2021-11-08 leer10103

    谢谢分享，非常好

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1071046, encodeId=6aa910e104619, content=非常好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=86, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=44b85482961, createdName=jianglan, createdTime=Wed Nov 17 10:52:09 CST 2021, time=2021-11-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1068115, encodeId=0f0910681157b, content=非常好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=106, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f3dd1885795, createdName=ms1812733236525890, createdTime=Mon Nov 08 13:58:58 CST 2021, time=2021-11-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1068047, encodeId=25a7106804eba, content=谢谢分享，非常好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=103, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c1f21454840, createdName=leer10103, createdTime=Mon Nov 08 09:29:31 CST 2021, time=2021-11-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1068042, encodeId=9b5610680425a, content=谢谢分享, beContent=null, objectType=guider, channel=null, level=null, likeNumber=106, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200804/f084cf5655364e4d991cbdc7e0a728c8/6011c4d8028d4509b1d5c06d7a966256.jpg, createdBy=6c405125125, createdName=凝香儿, createdTime=Mon Nov 08 09:23:20 CST 2021, time=2021-11-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1067999, encodeId=5329106e999e2, content=谢谢分享, beContent=null, objectType=guider, channel=null, level=null, likeNumber=112, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=644b2182796, createdName=1207866fm50(暂无昵称), createdTime=Mon Nov 08 08:34:30 CST 2021, time=2021-11-08, status=1, ipAttribution=)]
    2021-11-08 凝香儿

    谢谢分享

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1071046, encodeId=6aa910e104619, content=非常好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=86, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=44b85482961, createdName=jianglan, createdTime=Wed Nov 17 10:52:09 CST 2021, time=2021-11-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1068115, encodeId=0f0910681157b, content=非常好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=106, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f3dd1885795, createdName=ms1812733236525890, createdTime=Mon Nov 08 13:58:58 CST 2021, time=2021-11-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1068047, encodeId=25a7106804eba, content=谢谢分享，非常好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=103, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c1f21454840, createdName=leer10103, createdTime=Mon Nov 08 09:29:31 CST 2021, time=2021-11-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1068042, encodeId=9b5610680425a, content=谢谢分享, beContent=null, objectType=guider, channel=null, level=null, likeNumber=106, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200804/f084cf5655364e4d991cbdc7e0a728c8/6011c4d8028d4509b1d5c06d7a966256.jpg, createdBy=6c405125125, createdName=凝香儿, createdTime=Mon Nov 08 09:23:20 CST 2021, time=2021-11-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1067999, encodeId=5329106e999e2, content=谢谢分享, beContent=null, objectType=guider, channel=null, level=null, likeNumber=112, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=644b2182796, createdName=1207866fm50(暂无昵称), createdTime=Mon Nov 08 08:34:30 CST 2021, time=2021-11-08, status=1, ipAttribution=)]
    2021-11-08 1207866fm50(暂无昵称)

    谢谢分享

    0

相关指南

中国阿尔茨海默病痴呆诊疗指南(2020年版)

中国老年保健协会 阿尔茨海默病分会研究小组 · 2021-03-14

阿尔茨海默病的诊疗规范（2020年版）

中华人民共和国国家卫生健康委员会 · 2021-01-30

阿尔茨海默病康复管理中国专家共识（2019）

中华医学会神经病学分会 · 2020-01-30

中国阿尔茨海默病临床前期主观认知下降的诊治策略

暂未更新 ·

阿尔茨海默病MR检查规范中国专家共识

中华医学会放射学分会(CSR,chinese society of radiology) · 2019-08-30

适用于中国人群的阿尔茨海默病筛查和诊断框架

中国老年保健协会 阿尔茨海默病分会研究小组 · 2019-02-20

拓展阅读

2016 阿尔茨海默病创新药物临床试验中国专家共识

中国神经内科相关专家小组（统称） · 2016-02-29

2018中国痴呆与认知障碍诊治指南（二）：阿尔茨海默病诊治指南

中国医师协会神经内科医师分会 · 2018-04-03

阿尔茨海默病的中医诊疗共识

中华中医药学会(CACM,China Association of Chinese Medcine) 脑病分会 · 2018-05-02

2018中国痴呆与认知障碍诊治指南(七)：阿尔茨海默病的危险因素及其干预

中国医师协会神经内科医师分会 · 2018-05-22

2018中国痴呆与认知障碍诊治指南（六）：阿尔茨海默病痴呆前阶段

中国医师协会神经内科医师分会 · 2018-05-22

中国阿尔茨海默病临床前期主观认知下降诊断流程与规范专家共识

暂未更新 · 2019-02-12